NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Research Council (US) Committee for Capitalizing on Science, Technology, and Innovation: An Assessment of the Small Business Innovation Research Program; Wessner CW, editor. Venture Funding and the NIH SBIR Program. Washington (DC): National Academies Press (US); 2009.

Cover of Venture Funding and the NIH SBIR Program

Venture Funding and the NIH SBIR Program.

Show details

AVenture-funded Firms Among the 200 Most Prolific Winners of NIH Phase II Awards 1992-2002

Venture-funded Firms Among the 200 Most Prolific Winners of NIH Phase II Awards 1992-2002

Phase II AwardsAll AwardsVC Funding
Company NameFirst Phase II FundedStart of Latest Phase IINumber of NIH Phase II AwardsTotal SBIR Funding1st RoundMost Recent RoundNumber of RoundsTotal VC Funding
Aastrom Biosciences, Inc.2/1/19933/1/199954,905,4448/18/198910/30/2002836,385,000
Abiomed, Inc.3/1/19909/30/2000138,924,13212/1/198412/1/198413,000,000
Ambion, Inc.1/1/19939/1/200188,566,3875/1/20035/1/2003110,500,000
Biomedical Development Corporation5/1/19929/1/200096,967,86110/1/198710/1/19871150,000
Cambridge Neuroscience, Inc.9/27/19899/30/199732,267,0251/1/19866/21/1997935,879,000
Cengent Therapeutics, Inc.4/1/19999/1/199932,647,1881/11/199611/30/2000547,350,000
Centaur Pharmaceuticals, Inc.2/1/19949/30/199643,989,31612/1/199211/2/2001726,561,000
Conductus, Inc.4/15/19946/15/199432,904,8079/1/19873/27/2002645,700,000
Corixa Corporation9/15/19949/1/200087,971,06312/2/199410/2/1997359,330,000
Cortechs Labs, Inc.5/1/19986/15/200253,793,5531/9/198711/23/1992451,000,000
Cubist Pharmaceuticals, Inc.4/1/19954/1/199944,758,1379/1/19929/23/1998536,283,000
Cytel4/15/19947/20/200154,026,8678/1/198711/22/1991468,000,000
Diversa9/30/199611/1/199744,228,54612/1/19942/14/20005210,200,000
EKOS Corporation6/1/199812/1/200043,350,43810/1/19968/30/2001542,900,000
Electro-Optical Sciences, Inc.6/23/19934/19/200143,262,7641/15/19866/20/2003832,440,000
Epoch Biosciences9/1/19901/1/199943,238,2203/1/19867/1/19931329,980,000
Exocell, Inc.7/1/19927/1/200364,352,1503/1/19883/1/19881900,000
Foster Miller5/1/19904/15/20011011,827,6201/1/19801/1/19801750,000
Genaissance Pharmaceuticals, Inc.9/1/19938/29/199743,581,6114/1/19985/22/2000773,522,000
GenPharm International, Inc.4/1/19915/1/199241,748,67912/3/19884/1/1995940,100,000
Gliatech, Inc.2/24/19959/15/199833,342,6167/1/19886/1/1995732,596,000
Hawaii Biotech, Inc.7/1/19912/15/199979,643,0616/7/20026/6/200327,300,000
IDEC Pharmaceuticals Corporation8/15/19919/30/199732,441,5765/1/19862/1/1990443,870,000
Illumina, Inc.2/1/19997/1/200055,715,12311/30/199811/1/1999236,567,000
Immusol, Inc.9/30/19969/1/199943,347,9846/1/20019/24/2003223,500,000
Inotek Pharmaceuticals Corporation3/1/19988/1/20011429,421,6003/31/20043/31/2004120,000,000
Invitrogen Corporation9/1/19959/30/199844,254,1706/20/19976/20/1997115,000,000
Isis Pharmaceuticals9/1/19913/1/199943,210,2632/1/19898/11/1994617,490,000
Martek Biosciences Corporation9/30/19919/30/199533,220,6941/15/198611/23/1993522,750,000
Medical Physics Colorado5/1/19902/15/199242,698,14912/30/199112/30/1991120,000
Medimmune, Inc.3/1/19925/1/199632,912,9455/1/198812/9/19915143,850,000
Meridian Instruments, Inc.2/1/19915/1/199331,746,4135/1/198310/1/199343,557,000
Micronix Corporation8/1/19923/1/200164,264,3345/1/19817/1/19871576,598,000
Neurocrine Biosciences, Inc.9/30/19941/1/2001810,349,1749/25/19925/23/19961243,000,000
Nimbus Medical, Inc.9/1/19902/1/199543,147,9907/1/19863/1/198725,598,000
OSI Pharmaceuticals, Inc.5/1/19902/1/1997108,563,7223/1/19883/1/198814,000,000
Photon Imaging Corporation4/1/19957/1/200177,889,3079/1/19839/1/19831750,000
Physical Optics Corporation2/15/19939/30/2001109,782,7538/1/19878/1/199043,337,000
Physical Sciences, Inc.3/1/19903/15/2003118,175,3745/9/19957/1/19952492,000
Progenics Pharmaceuticals, Inc.9/1/19919/30/1996514,190,5071/1/199512/1/199515,670,000
RiboGene, Inc.8/1/19949/30/199643,727,1271/1/19902/1/19971443,577,000
Scios Nova, Inc.1/5/199211/1/199742,704,4766/1/19826/1/198215,425,000
Spencer Technologies9/1/19928/1/200043,334,1657/1/19977/1/19971435,000
Spire Corporation9/25/19892/15/200287,514,15011/1/19791/1/198733,750,000
State of The Art, Inc.8/23/19939/14/200088,231,0639/1/19831/1/198623,400,000
Stratagene Cloning Systems7/1/19914/7/199764,754,2144/1/198712/31/199221,873,000
Talaria Holdings, LLC7/12/19967/1/200187,068,6571/1/20014/1/2001228,673,000
Third Wave Technologies, Inc.4/1/19939/25/200153,778,2576/30/19957/26/2000578,064,000
Transoma Medical, Inc.4/1/19968/1/199933,384,7612/5/20022/5/2002112,075,000
Valentis3/26/19933/1/199743,350,0688/12/199310/1/2002647,405,000
Volumetrics Medical Imaging8/1/19936/1/200032,432,2551/1/19956/27/2003610,706,000
Total285272,332,4572241,592,258,000

Legend

34 Image nap12543.app1fu1.jpg First VC funding before first SBIR Phase II

17 Image nap12543.app1fu2.jpg Last VC funding after start of latest SBIR Phase II

6   Image nap12543.app1fu3.jpg First VC funding after last start date for SBIR Phase II

51 Image nap12543.app1fu4.jpg Total VC-funded companies identified as NIH SBIR Top 200

SOURCE: Award data: National Institutes of Health data delivered to the National Research Council; VC data: Thomson Financial, VentureSource, and RDNA databases.

Copyright © 2009, National Academy of Sciences.
Bookshelf ID: NBK26452

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.0M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...